BioStock: Arcede Pharma’s CEO on the right issue outcome

After this summer’s rights issue, Lund-based Arcede Pharma is now ready to continue work on the drug candidate RCD405. The issue was subscribed to approximately 72 per cent, which means that the company now has enough funds to continue development at an even pace. At the same time, the majority of the guarantors chose payment in newly subscribed units, a sign that they have great confidence in the company’s future. BioStock reached out to CEO Mia Lundblad to hear her thoughts on the outcome of the rights issue.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/10/arcede-pharmas-ceo-on-the-right-issue-outcome/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se